Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
Conclusion Our study shows that the SVR rates are similar in hemophilic and nonhemophilic patients with chronic HCV infection who receive PEG-IFN-α-2a plus RBV in Taiwan. The rate of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered from severe bleeding. However, large-scale, well-conducted studies are still needed to verify the treatment efficacy and safety.
Source: Journal of the Formosan Medical Association - Category: Journals (General) Source Type: research
More News: Bleeding | General Medicine | Haemophilia | Hemophilia | Hepatitis | Hepatitis C | Pegasys | Study | Thrombocytopenia | Virology